
Novel Drug Delivery Systems In Cancer Therapy Market
Novel Drug Delivery Systems in Cancer Therapy Market Forecasts to 2030 - Global Analysis By Drug Type (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Therapy Drugs, Hormonal Therapy Drugs, Gene Therapy Drugs, and Other Drug Types), Delivery Method, Drug Release Type, Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Novel Drug Delivery Systems in Cancer Therapy Market is accounted for $18.38 billion in 2024 and is expected to reach $31.69 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Advanced technologies created to improve the accurate and efficient distribution of cancer drugs to specific areas are referred to as novel drug delivery systems in cancer therapy. These systems, which include polymers, liposomes, and nanoparticles, are designed to decrease adverse effects, boost the bioavailability of medicinal compounds, and enhance treatment efficacy overall. These technologies provide promising options in cancer therapy by delivering medications directly to cancer cells or tumors, maximizing therapeutic efficacy while reducing harm to nearby healthy tissues.
Market Dynamics:
Driver:
Increased focus on personalized medicine
Growing emphasis on individualized care is a major factor propelling the market for novel drug delivery systems (NDDS) in cancer treatment. More accurate and efficient cancer treatments are made possible by personalized medicine, which adjusts treatment plans according to a patient's genetic composition, molecular profile, and tumor features. By making it easier to distribute medications to particular cancer cells, NDDS are essential to this strategy because they reduce harm to good tissue and improve therapy results. This accuracy lowers adverse effects and increases patient compliance with treatment plans. The creation of cutting-edge NDDS technology remains a vital part of contemporary cancer treatment plans, supporting market expansion as the need for tailored medicines increases.
Restraint:
High development costs
The sophisticated technologies needed for NDDS, like dendrimers, liposomes, and nanoparticles, require unique materials, intricate manufacturing procedures, and a great deal of experience. To guarantee the security and effectiveness of these systems, a great deal of preclinical and clinical testing is also required. Particularly in environments with limited resources, these exorbitant expenses may make it more difficult for smaller businesses to enter the market and may also lead to higher treatment costs, which would limit patient access. This means that the cost of developing NDDS prevents them from being widely adopted and commercialized.
Opportunity:
Growing research and development investments
The growing need for more effective, targeted, and personalized cancer treatments is driving an increase in research and development (R&D) investments in Novel Drug Delivery Systems (NDDS). R&D efforts are focused on developing advanced drug delivery technologies, such as nanoparticles, liposomes, and micelles, which enhance drug efficacy, minimize side effects, and improve patient compliance. Pharmaceutical and biotechnology companies are also investing heavily in innovative drug delivery systems to address the limitations of conventional therapies, such as poor bioavailability and systemic toxicity. Increased R&D investments accelerate the development of novel, more efficient, and safe drug delivery options for cancer treatment.
Threat:
Limited clinical evidence for certain delivery systems
Insufficient clinical data for specific Novel Drug Delivery Systems (NDDS) continues to be a major obstacle in the market for cancer treatments. Many NDDS methods, including specific nanoparticle formulations and gene-based delivery systems, have shown promise in preclinical research but have not yet proven to be consistently effective in human clinical trials. The widespread deployment of these technologies may be hampered by the potential delay in regulatory approval. For emerging NDDS technologies to succeed and be incorporated into standard cancer treatment, more thorough, extensive clinical trials are required to confirm the hazards and advantages of these technologies.
Covid-19 Impact
The COVID-19 pandemic has had a significant impact on the market for innovative drug delivery systems (NDDS) used in cancer treatment. The development and approval of new therapies have been delayed by disruptions in clinical trial procedures and supply chains. Cancer therapies also received less attention as a result of healthcare resources being redirected to COVID-19 management. Additionally, because cancer patients were more vulnerable during the pandemic, their treatment plans were more complex. This highlights the need for more efficient and focused medication delivery systems to improve patient outcomes in this difficult setting.
The chemotherapy drugs segment is expected to be the largest during the forecast period
The chemotherapy drugs segment is expected to account for the largest market share during the forecast period, due to their widespread use in cancer treatment. NDDS technologies enhance the effectiveness of chemotherapy by improving drug solubility, targeting cancer cells more precisely, and reducing systemic toxicity. These systems allow for controlled release, minimizing side effects and maximizing therapeutic impact. The growing need to improve chemotherapy outcomes while minimizing adverse effects fuels further development and integration of NDDS with chemotherapy agents.
The hospitals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hospitals segment is predicted to witness the highest growth rate, as primary centers for cancer treatment, hospitals are adopting advanced NDDS to enhance the efficacy of cancer therapies, reduce side effects, and improve patient outcomes. The increasing demand for personalized and targeted therapies in clinical settings pushes hospitals to invest in these innovative drug delivery systems, ultimately promoting their adoption and accelerating their integration into standard cancer treatment protocols.
Region with largest share:
During the forecast period, Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, improving healthcare infrastructure, and increasing healthcare expenditure. Governments are investing in advanced medical technologies, while growing awareness of personalized medicine further boosts demand for NDDS. Additionally, the region's large patient population, combined with rapid advancements in biotechnology and pharmaceutical industries, positions Asia-Pacific as a key market for the development and adoption of innovative cancer treatment solutions.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, advanced research and development capabilities, and high healthcare spending. The region's focus on precision medicine, along with a growing emphasis on personalized cancer treatments, fuels demand for NDDS technologies. Additionally, regulatory support from agencies like the FDA, along with the presence of leading pharmaceutical and biotech companies accelerates the development and adoption of innovative drug delivery systems for cancer therapy in North America.
Key players in the market
Some of the key players profiled in the Novel Drug Delivery Systems in Cancer Therapy Market include Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Roche Holding AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Amgen Inc., Celgene Corporation, Bayer AG, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Biocon Limited, and Mylan N.V.
Key Developments:
In June 2024, Bristol-Myers Squibb Company received FDA accelerated approval for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment for KRASG12C-mutated CRC patients who had undergone prior chemotherapy, based on ORR and DOR results.
In January 2024, Johnson & Johnson acquired Ambrx Biopharma, a clinical-stage biopharmaceutical company, in a cash merger deal valued at approximately USD 2.0 billion, with estimated cash on hand deducted.
Drug Types Covered:
• Chemotherapy Drugs
• Immunotherapy Drugs
• Targeted Therapy Drugs
• Hormonal Therapy Drugs
• Gene Therapy Drugs
• Other Drug Types
Delivery Methods Covered:
• Nanoparticle-Based Drug Delivery
• Microsphere-Based Drug Delivery
• Liposome-Based Drug Delivery
• Polymeric Drug Delivery
• Injection & Infusion Drug Delivery
• Implantable Drug Delivery Systems
• Other Delivery Methods
Drug Release Types Covered:
• Sustained Release
• Controlled Release
• Targeted Release
Technologies Covered:
• Nanotechnology
• Biotechnology
• Polymeric Drug Delivery Systems
• Liposomes and Nanoparticles
• Gene Therapy Delivery Systems
• Other Technologies
Applications Covered:
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Other Applications
End Users Covered:
• Hospitals
• Cancer Research Institutes
• Specialty Clinics
• Home Care Settings
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Type
5.1 Introduction
5.2 Chemotherapy Drugs
5.3 Immunotherapy Drugs
5.4 Targeted Therapy Drugs
5.5 Hormonal Therapy Drugs
5.6 Gene Therapy Drugs
5.7 Other Drug Types
6 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Delivery Method
6.1 Introduction
6.2 Nanoparticle-Based Drug Delivery
6.3 Microsphere-Based Drug Delivery
6.4 Liposome-Based Drug Delivery
6.5 Polymeric Drug Delivery
6.6 Injection & Infusion Drug Delivery
6.7 Implantable Drug Delivery Systems
6.8 Other Delivery Methods
7 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Release Type
7.1 Introduction
7.2 Sustained Release
7.3 Controlled Release
7.4 Targeted Release
8 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Technology
8.1 Introduction
8.2 Nanotechnology
8.3 Biotechnology
8.4 Polymeric Drug Delivery Systems
8.5 Liposomes and Nanoparticles
8.6 Gene Therapy Delivery Systems
8.7 Other Technologies
9 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Application
9.1 Introduction
9.2 Breast Cancer
9.3 Lung Cancer
9.4 Colorectal Cancer
9.5 Prostate Cancer
9.6 Leukemia
9.7 Other Applications
10 Global Novel Drug Delivery Systems in Cancer Therapy Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Cancer Research Institutes
10.4 Specialty Clinics
10.5 Home Care Settings
10.6 Other End Users
11 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Johnson & Johnson
13.2 Pfizer Inc.
13.3 Novartis AG
13.4 Merck & Co., Inc.
13.5 Roche Holding AG
13.6 Eli Lilly and Company
13.7 AbbVie Inc.
13.8 Bristol-Myers Squibb Company
13.9 Sanofi S.A.
13.10 AstraZeneca PLC
13.11 GlaxoSmithKline PLC
13.12 Amgen Inc.
13.13 Celgene Corporation
13.14 Bayer AG
13.15 Teva Pharmaceutical Industries Ltd.
13.16 Gilead Sciences, Inc.
13.17 Biocon Limited
13.18 Mylan N.V.
List of Tables
1 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Region (2022-2030) ($MN)
2 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Drug Type (2022-2030) ($MN)
3 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Chemotherapy Drugs (2022-2030) ($MN)
4 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Immunotherapy Drugs (2022-2030) ($MN)
5 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Targeted Therapy Drugs (2022-2030) ($MN)
6 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Hormonal Therapy Drugs (2022-2030) ($MN)
7 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Gene Therapy Drugs (2022-2030) ($MN)
8 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Drug Types (2022-2030) ($MN)
9 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Delivery Method (2022-2030) ($MN)
10 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Nanoparticle-Based Drug Delivery (2022-2030) ($MN)
11 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Microsphere-Based Drug Delivery (2022-2030) ($MN)
12 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Liposome-Based Drug Delivery (2022-2030) ($MN)
13 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Polymeric Drug Delivery (2022-2030) ($MN)
14 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Injection & Infusion Drug Delivery (2022-2030) ($MN)
15 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Implantable Drug Delivery Systems (2022-2030) ($MN)
16 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Delivery Methods (2022-2030) ($MN)
17 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Drug Release Type (2022-2030) ($MN)
18 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Sustained Release (2022-2030) ($MN)
19 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Controlled Release (2022-2030) ($MN)
20 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Targeted Release (2022-2030) ($MN)
21 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Technology (2022-2030) ($MN)
22 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Nanotechnology (2022-2030) ($MN)
23 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Biotechnology (2022-2030) ($MN)
24 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Polymeric Drug Delivery Systems (2022-2030) ($MN)
25 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Liposomes and Nanoparticles (2022-2030) ($MN)
26 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Gene Therapy Delivery Systems (2022-2030) ($MN)
27 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Technologies (2022-2030) ($MN)
28 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Application (2022-2030) ($MN)
29 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Breast Cancer (2022-2030) ($MN)
30 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Lung Cancer (2022-2030) ($MN)
31 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Colorectal Cancer (2022-2030) ($MN)
32 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Prostate Cancer (2022-2030) ($MN)
33 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Leukemia (2022-2030) ($MN)
34 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Applications (2022-2030) ($MN)
35 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By End User (2022-2030) ($MN)
36 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Hospitals (2022-2030) ($MN)
37 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Cancer Research Institutes (2022-2030) ($MN)
38 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Specialty Clinics (2022-2030) ($MN)
39 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Home Care Settings (2022-2030) ($MN)
40 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?

Assured Quality
Best in class reports with high standard of research integrity

24X7 Research Support
Continuous support to ensure the best customer experience.

Free Customization
Adding more values to your product of interest.

Safe & Secure Access
Providing a secured environment for all online transactions.

Trusted by 600+ Brands
Serving the most reputed brands across the world.